Maiva Pharma: The New Heart of Sterile Manufacturing

Maiva Pharma, a global contract development and manufacturing organisation (CDMO) focused on sterile injectables, has inaugurated its new state-of-the-art manufacturing facility at Shoolagiri in Tamil Nadu, marking a significant expansion of its production capabilities.

Spread across a 22-acre campus, the facility has been developed with advanced manufacturing technologies, flexible production platforms, and robust quality systems designed to meet the evolving requirements of global pharmaceutical markets. The site is intended to support the production of a broad portfolio of sterile injectable products while adhering to stringent international regulatory standards.

Upon full development, the facility will comprise six manufacturing lines capable of producing various sterile dosage forms, including vials, pre-filled syringes, cartridges, suspensions, and lyophilized products. As part of its first phase, Maiva Pharma has already commissioned three production lines, including a high-speed vial filling line, an integrated pre-filled syringe and cartridge line, and a dedicated lyophilization line.

The manufacturing infrastructure is supported by advanced chemical and microbiology laboratories, enabling comprehensive in-house quality control and testing capabilities. The facility also incorporates isolator-based manufacturing systems, which enhance sterility assurance, operational efficiency, and production flexibility while maintaining compliance with global quality and regulatory requirements.

The expansion significantly strengthens Maiva Pharma’s capacity to provide end-to-end services spanning product development, scale-up, and commercial manufacturing. By expanding its sterile injectable capabilities, the company aims to better serve pharmaceutical partners worldwide and reinforce its position as a trusted provider of high-quality injectable therapies across global healthcare markets.

News by Rahul Yelligetti.